EURO 2.7M Funding for Phase IIa Trials of CTH120 in Fragile X Syndrome

The public-private group, the biotechnology company CONNECT Therapeutics, the Genome Regulation Center (CRG), the Hospital del Mar Institute (IMIM) and the Parc Taulí Research and Innovation Institute (I3PT) received 2.7 million euros. They have received funding from the Ministry of Science, Innovation and Universities of Spain and the European Union through the NextGeneration EU program to initiate a phase 2a clinical trial of CTH120 to treat fragile X syndrome (FXS).

The Public Partnership Project funding complements private investments from CONNECT Therapeutics investors, including the Prous Institute for Biomedical Research, Inveready and CDTI Innvierte, and funding received from Retos Collaboración, CDTI NEOTEC and ENISA—public research project.

CTH120 is a novel drug designed using artificial intelligence to control neuroplasticity. CTH120 is completing Phase 1 clinical trials at the Hospital del Mar Research Institute in Barcelona, ​​led by Dr. Rafael de la Torre and Dr. Ana Aldea as principal investigators.

Final results from the Phase 1 clinical trials are expected in the first half of this year, and Phase 2a will begin in the first half of 2025. In this new phase, I3PT, with Dr. Ana Roche as Chief Investigator, joins CRG and the Hospital del Mar Institute as strategic partners. The project, led by CRG's Dr. Mara Dierssen, will also identify specific biomarkers to help assess response to treatment.

“We are excited to publish this announcement a few days before Rare Death Day. Finding cures for these diseases is a major public health challenge. "This funding from the Ministry of Science, Innovation and Universities of Spain allows us to advance the clinical development of specific treatments for FXS in collaboration with neuroscience centers and world-renowned researchers in the Barcelona region," explains the co-founder and CEO. Jordi Fabrega. By CONNECTA Therapeutics.